Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Commentary : Bullous Skin Diseases (CROSBI ID 173848)

Prilog u časopisu | uvodnik

Lipozenčić, Jasna ; Marinović, Branka Commentary : Bullous Skin Diseases // Clinics in dermatology, 29 (2011), 4; 353-354. doi: 10.1016/j.clindermatol.2011.01.004

Podaci o odgovornosti

Lipozenčić, Jasna ; Marinović, Branka

engleski

Commentary : Bullous Skin Diseases

Bullous dermatoses are characterized by vesicular-pustular eruptions and are classified as to whether they are hereditary or acquired diseases. The most important of the acquired bullous skin diseases are the pemphigus group, the pemphigoid group, acquired bullous epidermolysis, and dermatitis herpetiformis. Pemphigus is a group of autoimmune blistering diseases of the skin and mucous membranes mediated by immunoglobulin G (IgG) antibodies against the cadherin type of cell-cell adhesion molecules in desmosomes, desmogleins. Pemphigus group consists of three major forms: pemphigus vulgaris, pemphigus foliaceus (have IgG antibodies against desmoglein 3 and 1) and paraneoplastic pemphigus (IgG antibodies against plectin molecules in addition of desmogleins). For successful treatment of pemphigus, one must reduce autoantibody production, while blocking any of the several steps in the inflammatory cascade can treat bullous pemphigoid. Keeping the patient alive by suppressing disease, maintaining the quality of life, and minimizing drug side effects are major goals for the treatment of bullous skin diseases. When EBA is diagnosed, it is imperative to consider complications of disease and association with other inflammatory conditions that are frequently associated with EBA. Immunosuppressive therapy is usually required. Because neutrophils are important effector cells that mediate tissue damage in IgA dermatoses, responsiveness exhibit to sulfone therapy.

commentary; bullous skin diseases; pemphigus group

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

29 (4)

2011.

353-354

objavljeno

0738-081X

10.1016/j.clindermatol.2011.01.004

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost